ArticleEpilepsia2025
Mediators of epilepsy risk after traumatic brain injury: A 20-year U.S. veteran cohort study.
Article in Epilepsia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Bayesian age-period-cohort analysis and trend prediction of epilepsy disease burden in China, 1990-2021.Epileptic disorders : international epilepsy journal with videotape · 2026Article
- Mediators of epilepsy risk after traumatic brain injury: A 20-year U.S. veteran cohort study.Epilepsia · 2025Article
- From acute injury to chronic comorbidity: Interrupted time series modeling of traumatic brain injury impact among post-9/11 veterans.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTraumatic brain injury (TBI) is a significant risk factor for epilepsy, but little work has explored whether risk of epilepsy after TBI may operate through intermediary mechanisms. The objective of this study was to statistically screen for potentially mediating effects among 64 comorbidities for epilepsy risk following TBI among Post-9/11 U.S. veterans.
methodsThis longitudinal matched cohort study used an established algorithm to identify veterans in Department of Defense (DoD) and Veterans Health Administration (VHA) records with a history of the primary exposure, TBI, between 2003 and 2023, who were demographically matched 1:1 with veterans without history of TBI exposure from the same cohort. In the observation time window after index date, mediation models estimated the proportion eliminated of the total TBI-epilepsy relationship by other factors. Cox proportional hazard models were implemented for 64 comorbidities determined using International Classification of Diseases, Ninth/Tenth Revision (ICD-9/10) codes, each individually tested for the potential mediation of epilepsy onset after date of first TBI (index date), adjusting for demographic and military covariates. Age-stratified mediation analyses were conducted. Biologically plausible mechanisms were investigated.
resultsAmong N = 292 200 veterans in the TBI and matched groups, 8458 (2.9%) had an epilepsy diagnosis that met study criteria between 2003 and 2023. The adjusted hazard ratio (HR, 95% CI) for epilepsy given TBI was 6.76 [6.33-7.21]. The median duration between TBI documentation and epilepsy diagnosis was 3.3 years. In the observation time after index date (median duration: 12.2 years), Cox proportional hazard models identified the primary meditators of epilepsy risk after TBI as post-concussive symptoms (10.3%), cognitive dysfunction (7.0%), suicidal ideation/attempt (5.1%), overdose and drug abuse (3.8%-4.8%), and stroke (3.8%). SIGNIFICANCE: This study identified neurological conditions and symptoms that may play an intermediary role in the TBI-epilepsy relationship. Specific changes in health status after TBI may present useful targets for future trials and experimental approaches of PTE prevention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.